Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 1Lymphoid 1

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell 27Lymphoma, Mantle-Cell 14Lymphoma, Non-Hodgkin 13Lymphoma, B-Cell 11Lymphoma, B-Cell, Marginal Zone 7Hematologic Diseases 7Waldenstrom Macroglobulinemia 6Lymphoma 4Leukemia, B-Cell 4Lymphoma, Follicular 3Recurrence 2Lymphoma, Large B-Cell, Diffuse 2Leukemia, Lymphoid 2Leukemia 2Syndrome 1Multiple Myeloma 1Hematologic Neoplasms 1Dendritic Cell Sarcoma, Interdigitating 1Chromosome 17 deletion 1Burkitt Lymphoma 1

Interventions

Cyclophosphamide 73fludarabine phosphate 42Filgrastim 38Peripheral Blood Stem Cell Transplantation 35Radiotherapy 33Cyclosporine 32Busulfan 32Mycophenolic Acid 30Etoposide 29Antilymphocyte Serum 28Whole-Body Irradiation 26Methotrexate 25Melphalan 21Methylprednisolone 20Rituximab 19Vincristine 17Tacrolimus 17Cytarabine 17Cord Blood Stem Cell Transplantation 17Doxorubicin 14Prednisone 13Thiotepa 10Granulocyte Colony-Stimulating Factor 9Leucovorin 7Carboplatin 7fludarabine 6aldesleukin 6sargramostim 5Sirolimus 5Psychiatric Rehabilitation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Dendritic Cell Sarcoma, Interdigitating × pirtobrutinib × Lymphoid × Clear all
NCT03740529 2026-01-27

A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL

Eli Lilly and Company

Phase 1/2 Completed
803 enrolled 2 FDA
LymphoidOther hematologic neoplasmSarcoma

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Dendritic Cell Sarcoma, Interdigitating

Data powered by HemOnc (CC BY 4.0) Colophon âš¡